Neogen Corporation, a global leader in food safety solutions, has entered into a definitive agreement to divest its global genomics business to Zoetis Inc., the world's leading animal health company, for US$160 million, subject to customary closing adjustments. The divestiture, part of Neogen's broader portfolio review strategy aimed at simplifying its operations and concentrating on core strategic markets, is expected to close by the second half of 2026, pending regulatory approval and customary closing conditions. Net proceeds from the transaction are expected to be directed primarily toward debt reduction. The genomics segment, which operates under the GeneSeek brand, generated approximately US$90 million (approximately C$129.6 million) in revenue during fiscal year 2025. Neogen's Chief Executive Officer and President, Mike Nassif, stated that the transaction will accelerate de-leveraging efforts and enhance profitability, while enabling the company to focus on areas of significant competitive advantage in food and animal safety. GeneSeek has been recognized as a pioneer in advanced DNA testing for livestock and companion animal industries, offering genomic prediction tools through its Igenity and GGP portfolios and supported by the Encompass platform for genomic data integration. Guggenheim Securities LLC served as the exclusive financial advisor to Neogen on this transaction.